Enliven Therapeutics, Inc. (ELVN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$44.79-5.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ELVN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 99.0 | 85.9 | 80.8 | 64.6 | 31.0 | 20.5 | 32.2 |
| Operating Income | (135.4) | (119.7) | (104.6) | (83.5) | (38.8) | (24.8) | (41.7) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 21.9 | 16.0 | 15.5 | 11.9 | 1.1 | 0.0 | 0.3 |
| EBT, Incl. Unusual Items | — | — | — | — | 1.6 | (51.4) | — |
| Income Tax Expense | — | — | 0.2 | 0.0 | 0.0 | — | — |
| Net Income | |||||||
| Net Income | (113.5) | (103.7) | (89.0) | (71.6) | (37.7) | (24.7) | (41.4) |
| Per Share | |||||||
| Basic EPS | (1.46) | (1.83) | (1.89) | (2.01) | (12.05) | (10.73) | — |
| Diluted EPS | (1.46) | (1.83) | (1.89) | (2.01) | (12.05) | (10.73) | — |
| Basic Weighted Avg Shares | 78.0 | 56.7 | 47.1 | 35.5 | 3.1 | 2.3 | — |
| Diluted Weighted Avg Shares | 78.0 | 56.7 | 47.1 | 35.5 | 3.1 | 2.3 | — |
| Supplemental | |||||||
| EBITDA | — | (119.4) | (104.3) | (83.2) | (38.6) | (24.7) | — |
| EBIT | (135.4) | (119.7) | (104.6) | (83.5) | (38.8) | (24.8) | (41.7) |
| Effective Tax Rate | — | — | — | — | 0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.